Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Expectations By $0.07 EPS

Krystal Biotech (NASDAQ:KRYS) issued its quarterly earnings data on Monday. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07, Briefing.com reports. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. Krystal Biotech’s revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.67) EPS.

Krystal Biotech Price Performance

KRYS opened at $170.85 on Tuesday. The business has a fifty day moving average price of $182.28 and a 200 day moving average price of $180.12. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34. The stock has a market capitalization of $4.91 billion, a price-to-earnings ratio of 46.81 and a beta of 0.82.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KRYS. Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. HC Wainwright boosted their target price on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $196.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).